77 completed, 20 unknown, 14 recruiting, 8 terminated. 33 Phase 2, 30 Phase 3, 17 Not applicable, 9 Phase 4, 8 Phase 1.
Follow Tuberculosis, Multidrug-Resistant: new trials by email Literature Review of Tuberculosis, Multidrug-Resistant trials Research Report on Tuberculosis, Multidrug-Resistant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis MDR-END Plus regimen, Standard-of-care (SoC) treatment - Rifampicin-Resistant Tuberculosis | Phase 3 | Not yet recruiting | Seoul National University Hospital | 294 | 2026-10-01 | 2026-06-30 |
| Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR) Bedaquiline Oral Tablet - MDR-TB, Tuberculosis Multi Drug Resistant Active | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 55 | 2026-09-11 | 2026-09-16 |
| Bioneer Q-RFIA Clinical Evaluation Estimate the diagnostic accuracy of the Bioneer Accupower Q-RFIA PCR kit on IRON qPCR for MTB detection using culture as reference standard. Estimate the diagnostic accuracy of the Bioneer Ac - Tuberculosis, Multidrug-Resistant | Recruiting | Foundation for Innovative New Diagnostics, Switzerland | 2350 | 2026-06-30 | 2026-09-23 | |
| Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis Targeted sequencing using the GenoScreen Deeplex assay - Tuberculosis, Multidrug-Resistant | Not applicable | Not yet recruiting | University of Cape Town | 280 | 2026-06-01 | 2026-05-06 |
| Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis Therapeutic Drug Monitoring for Linezolid - Rifampin-resistant Tuberculosis, Drug-resistant Tuberculosis | Not applicable | Recruiting | Albert Einstein College of Medicine | 280 | 2026-04-07 | 2026-05-04 |
| Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment Linezolid dose personalization based on TDM - Linezolid, Tuberculosis Multi Drug Resistant Active | Phase 4 | Recruiting | Marco Schiuma | 150 | 2026-04-01 | 2026-05-13 |
| Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) Acetohydroxamic Acid, Placebo - Multidrug-Resistant Tuberculosis, Rifampicin-resistant Tuberculosis | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 120 | 2026-02-21 | 2026-02-06 |
| Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort BLMZ - Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Not yet recruiting | Beijing Chest Hospital | 120 | 2025-12-01 | 2025-12-08 |
| Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis Bedaquiline, Linezolid, Pretomanid - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 / Phase 3 | Recruiting | University of California, San Francisco | 400 | 2025-10-03 | 2026-09-02 |
| Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region Tuberculosis, Multi Drug Resistant, Strains | Not yet recruiting | Centre de Recherche Médicale de Lambaréné | 460 | 2025-07-01 | 2025-06-12 | |
| Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry) No intervention (observational study) - Tuberculosis, Multidrug-Resistant | Not yet recruiting | Korea Otsuka Pharmaceutical Co., Ltd. | 222 | 2024-11-30 | 2024-11-05 | |
| Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort bedaquiline, delamanid, linezolid - Drug-resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Active not recruiting | Huashan Hospital | 120 | 2024-11-27 | 2025-09-02 |
| Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis Targeted next-generation sequencing - Drug-resistant Tuberculosis, HIV Coinfection | Not applicable | Recruiting | University of California, San Francisco | 2500 | 2024-08-01 | 2026-01-26 |
| HIV and Multi-Drug Resistant Tuberculosis: a Study on Clinical Outcomes Examination of HIV Infection in Patients with Multi-Drug Resistant Tuberculosis (MDR-TB) - HIV Infection, MDR-TB | Completed | Zahedan University of Medical Sciences | 222128 | 2024-05-15 | 2024-11-04 | |
| Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis JDB0131, Delamanid, Ethylpyrazine rifampicide (II) - Drug-resistant Tuberculosis | Phase 2 | Unknown | Beijing Chest Hospital | 52 | 2023-10-31 | 2024-01-25 |
| Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment Nurse-Led Treatment in Primary Care - Drug Resistant Tuberculosis | Not applicable | Recruiting | Johns Hopkins University | 2944 | 2023-09-04 | 2025-10-20 |
| Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) - Pulmonary Tuberculosis | Phase 2 | Terminated | Gates Medical Research Institute | 93 | 2023-07-26 | 2026-05-20 |
| Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB) Tedizolid arm (SIVEXTRO®), Linezolid arm (ZYVOXID®), Standard quadruple therapy arm - Tuberculosis, Multidrug Resistant Tuberculosis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 60 | 2023-04-20 | 2025-02-03 |
| An Adaptive Randomized Controlled Trial Adherence support intevention - Multi Drug Resistant Tuberculosis, HIV Infections | Not applicable | Recruiting | Columbia University | 360 | 2023-03-07 | 2026-05-28 |
| Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis Amikacin - Tuberculosis, Multidrug-Resistant | Phase 2 | Unknown | Rwanda Biomedical Centre | 20 | 2023-03-01 | 2023-03-29 |
Showing 20 of 130. Sign in to see all of them.
Tuberculosis (57) · Tuberculosis, Pulmonary (30) · Extensively Drug-Resistant Tuberculosis (23) · Mycobacterium Infections (6) · Bacterial Infections (5) · Latent Tuberculosis (5) · Disease (3) · HIV Infections (3) · Lung Diseases (2) · Medication Adherence (2) · Patient Compliance (2) · Peripheral Nervous System Diseases (2) · Acquired Immunodeficiency Syndrome (1) · Actinomycetales Infections (1)
Bacterial Infections and Mycoses (130) · Infections (130) · Actinomycetales Infections (129) · Gram-Positive Bacterial Infections (129) · Bacterial Infections (125) · Mycobacterium Infections (124) · Tuberculosis (73) · Respiratory Tract Diseases (30) · Respiratory Tract Infections (30) · Lung Diseases (28) · Latent Infection (5) · Blood-Borne Infections (4) · Communicable Diseases (4) · Genital Diseases (4) · Immune System Diseases (4)
bedaquiline (28) · Linezolid (21) · OPC-67683 (18) · Pyrazinamide (14) · Clofazimine (13) · Moxifloxacin (13) · pretomanid (13) · Levofloxacin (11) · Isoniazid (10) · Rifampin (5) · Ethambutol (4) · Clinical Protocols (3) · Cycloserine (2) · Kanamycin (2) · Prothionamide (2)
Global Alliance for TB Drug Development (9) · Huashan Hospital (7) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Otsuka Pharmaceutical Development & Commercialization, Inc. (6) · Beijing Chest Hospital (5) · Foundation for Innovative New Diagnostics, Switzerland (5) · Medecins Sans Frontieres, Netherlands (5) · University Medical Center Groningen (4) · University of Cape Town (4) · Assistance Publique - Hôpitaux de Paris (3) · Boston University (3) · Centers for Disease Control and Prevention (3) · Janssen Infectious Diseases BVBA (3) · Research Center Borstel (3) · Seoul National University Hospital (3)
South Africa (45) · China (25) · Peru (18) · Philippines (15) · Georgia (12) · India (10) · South Korea (10) · Ukraine (9) · Latvia (8) · Moldova (8) · Uganda (8) · Belarus (7) · Russia (7) · United States (7) · Brazil (6)
Antonio Lombardi, MD (4) · Wenhong Zhang, PhD (3) · Carole Mitnick, Sc.D (2) · Clifton E Barry, Ph.D. (2) · Lorenzo Guglielmetti, MD (2) · Wenhong Zhang, PhD,MD (2) · Aldar Bourinbaiar, PhD, MD/PhD (1) · Amirkan A Azembayev, Cond.Phar.Sc. (1) · Amita Gupta, MD, MHS (1) · Andrew Nunn, PhD (1) · Anjanette Reyes-De Leon, MD (1) · Anneke Hesseling, MD, PhD (1)
PMID 20442432, PMID 26647431, PMID 27868466, PMID 35404075, PMID 37035978, PMID 11326818, PMID 15971391, PMID 19383184, PMID 19494215, PMID 21182457, PMID 21828024, PMID 22397570, PMID 22401633, PMID 22670901, PMID 23075177, PMID 23131255, PMID 23520311, PMID 23611033, PMID 23826878, PMID 23927582, PMID 24721980, PMID 25097082, PMID 25140958, PMID 25216831, PMID 25216832, PMID 25377177, PMID 26871879, PMID 26929418, PMID 27090176, PMID 27576542, PMID 28007659, PMID 28381434, PMID 28404672, PMID 28424085, PMID 28475735, PMID 28507113, PMID 28507117, PMID 29178937, PMID 29499645, PMID 30012767, PMID 30024924, PMID 30287613, PMID 30373800, PMID 30514514, PMID 30630778, PMID 30651149, PMID 30782999, PMID 30865791, PMID 31649017, PMID 31676905
2008 (2), 2009 (1), 2014 (1), 2016 (1), F31AI075897 (1), R01AI057786 (1), R01AI146095 (1), R01AI153213 (1), R01AI167795 (1), R01AI177135 (1), R01AI184416 (1), U01AI082229 (1), U01AI100015 (1), U01AI100805 (1), U01AI152980 (1)